RPG Life Sciences Approves ₹135 Crore API Business Acquisition

Board approved RPG Active Pharma's BTA to acquire Raghava Life Sciences' API and intermediates business for cash consideration up to Rs 135 Cr. First acquisition advances RPG's API expansion strategy, adding manufacturing and R&D facilities plus 29 API molecules, including 22 commercialized products. Acquired business reported FY26 revenue of about Rs 19 Cr; completion is subject to approvals within 30 days, while profitability and synergies remain undisclosed.